Drug Pipeline

Ceritinib Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
5
Active Studies
1
Recruiting
4
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-16 NCT03611738
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC		 date change Completion pushed: 2026-04 -> 2027-03
Active Studies by Phase
Phase 4
1
Phase 2
1
Phase 1
3
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT02584933 Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib… ALK Positive Malignancies Active, Not Recruiting
Phase 2
NCT02559778 Pediatric Precision Laboratory Advanced Neuroblastoma Therapy Neuroblastoma Recruiting
Phase 1
NCT03611738 Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC Non-small Cell Lung Cancer Active, Not Recruiting
NCT02321501 Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid… ALK Positive Active, Not Recruiting
NCT02393625 Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With… ALK-positive NSCLC Active, Not Recruiting
Sponsors Running Ceritinib Trials
Novartis Pharmaceuticals (2) M.D. Anderson Cancer Center (1) Giselle Sholler (1) H. Lee Moffitt Cancer Center and Research Institute (1)
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (3) Lung Cancer (1)
Get alerts when Ceritinib trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free